Proteogenomic screen of 5,411 plasma proteins maps new drug target candidates in sickle cell disease

A study combining genomics and high-throughput proteomics in 343 sickle cell disease patients has identified plasma protein associations that could guide future therapeutic development.

Published · AI-drafted summary based on 1 public source
Illustration for generic story
Illustrative image — not from the source article.
Share

Researchers led by Cristian Groza, Guillaume Lettre, and colleagues have published a proteogenomic analysis of plasma proteins in sickle cell disease (SCD) patients, with results appearing in PLOS Genetics. The team measured levels of 5,411 plasma proteins in 343 SCD patients and tested associations between those protein levels and common genetic variation — an approach that integrates genomics with high-throughput proteomics to surface candidate drug targets.

Sickle cell disease, caused by mutations in the β-globin gene, affects more than seven million people worldwide and has a limited therapeutic landscape. By pairing protein-level measurements with genetic data, the analysis can identify proteins whose circulating levels are under genetic control and whose variation tracks with disease-relevant biology — a step that may help prioritise which molecular pathways are worth pursuing in drug discovery.

The study does not propose clinical interventions. Rather, it offers a large-scale catalogue of genetically influenced plasma proteins in SCD patients that researchers can mine when evaluating potential drug targets. The dataset represents one of the most comprehensive proteogenomic resources assembled specifically for this condition to date, and may also serve as a reference for future studies interrogating the role of the plasma proteome in haematological disease.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

Sickle cell disease is a blood disorder caused by a change in one gene, called the β-globin gene, which affects how red blood cells are shaped. More than seven million people around the world live with this condition, and the number of medicines available to treat it is still small.

Researchers have now measured more than 5,000 proteins found in the blood of people with sickle cell disease and looked for connections between those protein levels and the patients' genetic make-up. The idea is that if a protein's level in the blood is shaped by a gene, that protein might be a useful target for a future medicine.

This kind of large-scale catalogue does not lead directly to new treatments — that takes many more years of research — but it gives scientists a detailed map to work from when deciding which biological pathways to study next.

This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source PLOS Genetics · 2026-11-16
    Proteogenomic analysis of 5,411 plasma proteins in sickle cell disease patients

Tags

sickle-cell-disease proteogenomics plasma-proteome drug-targets plos-genetics haematology population-genomics
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List